KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $28.3 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 49.21% year-over-year to $28.3 million; the TTM value through Mar 2026 reached $28.3 million, down 49.21%, while the annual FY2025 figure was $28.1 million, 45.85% down from the prior year.
  • Other Non-Current Liabilities hit $28.3 million in Q1 2026 for Ionis Pharmaceuticals, up from $28.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $538.1 million in Q3 2024 and bottomed at $7.5 million in Q1 2023.
  • Average Other Non-Current Liabilities over 4 years is $188.1 million, with a median of $51.9 million recorded in 2024.
  • Year-over-year, Other Non-Current Liabilities surged 1002.65% in 2024 and then plummeted 94.65% in 2025.
  • Ionis Pharmaceuticals' Other Non-Current Liabilities stood at $513.7 million in 2023, then tumbled by 89.89% to $51.9 million in 2024, then plummeted by 45.85% to $28.1 million in 2025, then grew by 0.55% to $28.3 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $28.3 million, $28.1 million, and $28.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.